← boardnext 2027-11-30
ARVN
Arvinas Inc.distress 1/10 · well-funded / low risk$8.14-1%today-41% from 52w high
Lead: Parkinson's disease · est. market ~$6B (approx, global)
Revenue
$16M
Liquidity
$615M
Runway
2.4 yrs
Shares 1y
-12%
Price & events
-35.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+1.4%
1W
+0.0%
1M
-21.9%
3M
-36.9%
6M
+3.4%
1Y
-72.9%
2Y
-91.5%
5Y
-90.3%
All
Overview
- Market Cap
- $525.20M
- Enterprise Value
- $438.20M
- Volume
- 33.04K
- 52 Week Range
- $6.24 – $13.83
- Total Shares
- 64.52M
- Float Shares
- 55.80M
- Short %
- 7.73%
- % Held by Insiders
- 7.91%
- % Held by Institutions
- 82.59%
- RVOL
- 0.05x
- Beta
- 1.75
Pipeline stages · 1 programs
ARV-393, Glofitamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-11-30 Estimated 50% readout ~2028-01-14 | Phase 1/2 | ARV-806 | KRAS G12D Mutation, Advanced Solid Cancer | — | active not recruiting |
| 2028-03 Estimated 50% readout ~2028-03-31 | Phase 1 | ARV-393, Glofitamab | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | — | recruiting |
Catalyst news & presentations · 12
- 2026Guided 40%conferencedata presentationsecondaryPhase 1ARV-102 · Initial data from multiple dose cohort of Phase 1 clinical trial ARV-102-103 in patients with Parkinson's disease.SEC 8-K
- 2026Guided 40%trial initiationsecondaryPhase 1ARV-393 · Plans to add glofitamab combination cohort in ongoing Phase 1 trial.SEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondaryPhase 1/2ARV-102 · Intended initiation of Phase 1b clinical trialSEC 8-K
- 2026-06-11partnershipVEPPANU (vepdegestrant) · Rigel licenses exclusive global development and commercialization rights from Arvinas and Pfizer, paying $70M upfront and up to $320M in milestones.SEC 8-K
- June 5, 2026PDUFAPDUFAVEPPANU (vepdegestrant) · FDA-assigned PDUFA date for VEPPANU.SEC 8-K
- Wednesday, June 3, 2026conferencedata presentationsecondaryInvestor presentation at Jefferies Global Healthcare Conference.SEC 8-K
- second half of 2025regulatory submissionFiled (NDA/BLA)vepdegestrant · Plan to submit NDA to FDASEC 8-K
- October 20, 2025conferencedata presentationsecondaryPhase 3vepdegestrant · PRO data from VERITAC-2 presented at ESMO 2025SEC 8-K
- October 5, 2025conferencedata presentationsecondaryPhase 1ARV-102 · Late-breaking positive Phase 1 clinical trial data for ARV-102 at 2025 International Congress of Parkinson’s Disease and Movement Disorders.SEC 8-K
- 2025-05-01trial discontinuedvepdegestrant · Removed second-line Phase 3 combination trial with a CDK4/6 inhibitor from joint development plan.SEC 8-K
- April 28, 2025conferencedata presentationsecondaryARV-393 · Poster presentation at AACR 2025 of preclinical combination studies of ARV-393 PROTAC BCL6 degrader.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $15 (+82% upside) · 14 analysts
- 2026-06-03Stephens & Co.Overweight
- 2026-05-13BTIGBuy
- 2026-05-13BarclaysOverweight
- 2026-05-04CitigroupBuy
- 2026-03-19CitigroupBuy
- 2026-03-19BTIGBuy
Competitors — Parkinson's disease
- DNLIDenali Therapeutics Inc.$3.6B · D2
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- OVIDOvid Therapeutics Inc.$442M · D4
- IKTInhibikase Therapeutics, Inc.$289M · D4
- NAGENiagen Bioscience, Inc.$264M · D1
- VYGRVoyager Therapeutics, Inc.$184M · D4
- GANXGain Therapeutics, Inc.$78M · D3
- SERSerina Therapeutics, Inc.$33M · D6
- ALMSALUMIS INC.— · D4
Recent news
- 2026-07-18ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
- 2026-07-17Arvinas (ARVN) AGM 2026 Summary - Quartr
- 2026-07-17Arvinas (ARVN) Proxy filing Summary - Quartr
- 2026-07-17Trading the Move, Not the Narrative: (ARVN) Edition - Stock Traders Daily
- 2026-07-09Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares - Stock Titan
- 2026-07-07ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
- 2026-06-26Arvinas (ARVN) director receives new RSU and stock option awards - Stock Titan
- 2026-06-26Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4 - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.